000119840 001__ 119840
000119840 005__ 20240319081011.0
000119840 0247_ $$2doi$$a10.3390/pharmaceutics14071417
000119840 0248_ $$2sideral$$a130351
000119840 037__ $$aART-2022-130351
000119840 041__ $$aeng
000119840 100__ $$aFernández-Carro, Estibaliz
000119840 245__ $$aModeling an optimal 3D Skin-on-Chip within microfluidic devices for pharmacological studies
000119840 260__ $$c2022
000119840 5060_ $$aAccess copy available to the general public$$fUnrestricted
000119840 5203_ $$aPreclinical research remains hampered by an inadequate representation of human tissue environments which results in inaccurate predictions of a drug candidate''s effects and target''s suitability. While human 2D and 3D cell cultures and organoids have been extensively improved to mimic the precise structure and function of human tissues, major challenges persist since only few of these models adequately represent the complexity of human tissues. The development of skin-on-chip technology has allowed the transition from static 3D cultures to dynamic 3D cultures resembling human physiology. The integration of vasculature, immune system, or the resident microbiome in the next generation of SoC, with continuous detection of changes in metabolism, would potentially overcome the current limitations, providing reliable and robust results and mimicking the complex human skin. This review aims to provide an overview of the biological skin constituents and mechanical requirements that should be incorporated in a human skin-on-chip, permitting pharmacological, toxicological, and cosmetic tests closer to reality.
000119840 536__ $$9info:eu-repo/grantAgreement/ES/DGA/GIS096$$9info:eu-repo/grantAgreement/ES/DGA/LMP233_21
000119840 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000119840 590__ $$a5.4$$b2022
000119840 592__ $$a0.795$$b2022
000119840 591__ $$aPHARMACOLOGY & PHARMACY$$b50 / 278 = 0.18$$c2022$$dQ1$$eT1
000119840 593__ $$aPharmaceutical Science$$c2022$$dQ1
000119840 594__ $$a6.9$$b2022
000119840 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000119840 700__ $$aAngenent, Maricke
000119840 700__ $$aGracia-Cazaña, Tamara$$uUniversidad de Zaragoza
000119840 700__ $$0(orcid)0000-0001-8034-3617$$aGilaberte, Yolanda$$uUniversidad de Zaragoza
000119840 700__ $$0(orcid)0000-0002-7854-8856$$aAlcaine, Clara$$uUniversidad de Zaragoza
000119840 700__ $$0(orcid)0000-0002-8666-622X$$aCiriza, Jesús$$uUniversidad de Zaragoza
000119840 7102_ $$11006$$2255$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Enfermería
000119840 7102_ $$11003$$2443$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Histología
000119840 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología
000119840 773__ $$g14, 7 (2022), 1417 [22 pp.]$$pPharmaceutics$$tPharmaceutics$$x1999-4923
000119840 8564_ $$s2419088$$uhttps://zaguan.unizar.es/record/119840/files/texto_completo.pdf$$yVersión publicada
000119840 8564_ $$s2776957$$uhttps://zaguan.unizar.es/record/119840/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000119840 909CO $$ooai:zaguan.unizar.es:119840$$particulos$$pdriver
000119840 951__ $$a2024-03-18-15:09:32
000119840 980__ $$aARTICLE